Dr. Scott Braunstein was appointed Chairman of Marinus Pharmaceuticals’ Board in November 2022. He has held the position of Chief Executive Officer at Marinus since August 2019 and has been a valued member of its Board since September 2018. Under Dr. Braunstein’s leadership, Marinus received its first FDA-approval in March 2022.
Dr. Braunstein brings over 30 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is currently an operating partner at Aisling Capital. He most recently served as chief strategy officer and chief operating officer at Pacira Biosciences, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 13 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as portfolio manager of the JP Morgan Global Healthcare Fund responsible for managing investments in pharmaceuticals, biotechnology and medical devices.
Dr. Braunstein is currently on the board of Trevena, Inc., Caribou Biosciences, Inc., One Biosciences and SiteOne Therapeutics, Inc. He also serves on the advisory board of Life Science Cares. He previously served on the boards of Constellation Pharmaceuticals (acquired by MorphoSys AG in July 2021), Ziopharm Oncology, Inc., Esperion Therapeutics, Inc. and Protara Therapeutics, Inc. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University.